Magnetic pulses target teen depression

NCT ID NCT05544071

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 ยท Last updated Sep 21, 2026

Summary

Researchers test whether repetitive transcranial magnetic stimulation (rTMS) can reduce depression and anhedonia, the inability to feel pleasure, in teenagers. The trial enrolls 88 adolescents with major depressive disorder who score high on measures of depression and anhedonia. Half receive active rTMS aimed at a specific brain circuit, and half receive a sham stimulation. The main goal is to see if the active treatment improves pleasure scores after eight weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
repetitive transcranial magnetic stimulation (rTMS)
What this could lead to
If it works, this could offer a non-drug option for teenagers whose depression and loss of pleasure have not improved with standard treatments.
What could go wrong
The trial is small and early, so results may not hold up in larger groups. Brain stimulation can cause scalp discomfort or headaches, and some teens may not respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

88 people

The number who actually took part.

Started

Feb 2023

Finished

Jul 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

13 to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female, 13 to 18 years of age. * According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Diagnosed with Major Depressive Disorder (MDD) and currently experiencing a Major Depressive Episode (MDE). * Meet the threshold on the total HAMD17 score of \>/=17 at both screening and baseline visits (Day -7 and Day 0). * Meet the threshold on the total SHAPS score of \>/=20 at both screening and baseline visits (Day -7 and Day 0). * Not take any antidepressants for two or more weeks before screening. * In good general health, as ascertained by medical history. * After fully understanding the treatment of transcranial magnetic stimulation, willing to cooperate with the treatment actively and able to provide informed consent. Exclusion Criteria: * Current diagnosis of a Substance Use Disorder, with the exception of nicotine and caffeine dependence. * Current diagnosis of mental disorders other than Dysthymic Disorder, Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder, Agoraphobia, or Specific Phobia (unless one of these is clinically unstable, and/or the focus of the participant's treatment for the past six months or more). * History of schizophrenia or schizoaffective disorders, or any history of psychotic symptoms in the current or previous depressive episodes. * Any other Mental Disorders, Personality Disorders, Intellectual Disability, which at screening is clinically predominant to their MDD. * Has a clinically significant abnormality on the screening examination that might affect safety, study participation, or confound interpretation of study results. * Any current or past history of any physical condition which in the investigator's opinion might put the subject at risk or interfere with study results interpretation. * Participation in any clinical trial with an investigational drug or device within the past month or concurrent to study participation. * History of electronic instrument or metal in the head or skull. * History of epilepsy. * History of cardiovascular disease or cardiac event. * History of OCD. * History of autism spectrum disorder. * History of rTMS exposure. * Other situations judged by the researchers to be unsuitable for the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Major depressive disorder are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Xijing Hospital

    Xi'an, Shaanxi, 710032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.